Producers Online
L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique1.L’analyse…
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1…
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable…
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated…
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulvestrant alone1The PIK3CA mutation…
Започнатото строителство според застроената площ е най-малкото от 2021 година насам. През първото тримесечие на 2025 година са започнати жилищни сгради с площ от 739 хил. кв. метра, от които…
QUÉBEC, 31 mai 2025 (GLOBE NEWSWIRE) -- Robex Resources Inc. (« Robex » ou la « Société ») (TSX-V : RBX), producteur et développeur aurifère ouest-africain, a le plaisir d’annoncer…
Честит Гергьовден!Нека Свети Георги бъде наш щит срещу злото, меч в борбата със злото и съмненията и пламък, който осветява пътя ни най-накрая към една независима държава.От нас зависи пожеланията…
STADT QUÉBEC, May 31, 2025 (GLOBE NEWSWIRE) -- Der westafrikanische Goldproduzent und -erschließer Robex Resources Inc („Robex“ oder das „Unternehmen“) (TSX-V: RBX) freut sich bekannt zu geben, dass das Unternehmen…